Federal Register of Legislation - Australian Government

Primary content

SLI 2009 No. 372 Regulations as amended, taking into account amendments up to National Health (Pharmaceuticals and Vaccines—Cost Recovery) Amendment (Vaccine Advice) Regulations 2019
Administered by: Health
Registered 11 Jul 2019
Start Date 01 Jul 2019

Commonwealth Coat of Arms of Australia

National Health (Pharmaceuticals and Vaccines—Cost Recovery) Regulations 2009

Select Legislative Instrument No. 372, 2009

made under the

National Health Act 1953

Compilation No. 4

Compilation date:                              1 July 2019

Includes amendments up to:            F2019L00931

Registered:                                         11 July 2019

 

About this compilation

This compilation

This is a compilation of the National Health (Pharmaceuticals and Vaccines—Cost Recovery) Regulations 2009 that shows the text of the law as amended and in force on 1 July 2019 (the compilation date).

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

Self‑repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

  

  

  


Contents

Part 1—Preliminary                                                                                                             1

1.1......... Name of Regulations........................................................................... 1

1.3......... Definitions.......................................................................................... 1

Part 1A—Pre‑submission services                                                                               3

Division 1A.1—Providing ATAGI advice                                                         3

1A.1...... Fees for providing ATAGI advice...................................................... 3

1A.2...... Partial exemption from usual ATAGI fee for simple ATAGI applications              3

1A.3...... How to make an ATAGI application.................................................. 4

1A.4...... Notification (including invoicing of fees)............................................ 4

1A.5...... Withdrawal of an ATAGI application................................................. 5

1A.6...... Resending ATAGI applications.......................................................... 5

Division 1A.2—Holding pre‑submission meetings                                         6

1A.7...... Fees for holding pre‑submission meetings.......................................... 6

1A.8...... How to apply for a pre‑submission meeting....................................... 6

1A.9...... Agreeing to hold a pre‑submission meeting........................................ 6

1A.10.... Notification (including invoicing of fees)............................................ 6

1A.11.... Withdrawal of a meeting application................................................... 7

1A.12.... Resending meeting applications.......................................................... 7

Part 2—Submission services                                                                                            8

Division 2.1A—Preliminary                                                                                      8

2.1A...... Simplified outline of this Part.............................................................. 8

Division 2.1—Submissions to the Committee or Minister etc.                9

Subdivision 1—Fees and associated applications                                              9

2.1......... Which submissions (also known as applications for services) are relevant?            9

2.2......... Fees for submission services.............................................................. 9

Subdivision 2—Applications that are major                                                     10

2.3......... Major—applications to list................................................................ 10

2.4......... Major—health advantage test............................................................ 10

2.5......... Applications excluded from major category...................................... 10

2.6......... Requirements for major applications................................................. 10

Subdivision 3—Applications that are minor                                                     11

2.7......... Minor—applications to change listings............................................. 11

2.8......... Minor—clinical need and effectiveness test...................................... 11

2.9......... Minor—exceptions to new brand of existing pharmaceutical item category             11

2.10....... Minor—applications that are resubmissions..................................... 12

2.11....... Minor—medicinal foods................................................................... 12

Subdivision 4—Other categories                                                                          12

2.12....... Applications that are Committee Secretariat...................................... 12

2.13....... Committee Secretariat—exceptions to new brand of existing pharmaceutical item category     13

2.14....... Applications that are new brand of existing pharmaceutical item...... 13

Division 2.2—Application procedure including prior notice                 14

2.15....... Prior notice needed for major or minor applications to the Committee 14

2.16....... How to apply for submission services.............................................. 15

2.17....... Notification (including invoicing of fees).......................................... 15

2.18....... Withdrawal........................................................................................ 16

2.19....... Resending applications...................................................................... 17

Division 2.3—Validating evaluation categories and assessing applications        18

2.20....... Validating an application’s evaluation category................................. 18

2.21....... Assessing applications...................................................................... 18

Part 3—Pricing services                                                                                                   20

Division 3.1—Preliminary                                                                                        20

3.1......... Simplified outline of this Part............................................................ 20

Division 3.2—Fees and associated applications                                            21

3.2......... Applications for pricing services....................................................... 21

3.3......... Fees for providing pricing services................................................... 21

3.4......... Pricing Pathway A applications........................................................ 22

3.5......... Pricing Pathway B applications......................................................... 22

3.6......... Pricing Pathway C applications......................................................... 22

3.7......... When pricing terms are substantially similar to those appropriate for the new drugs               23

3.8......... Pricing Pathway D applications........................................................ 24

3.9......... Pricing Secretariat applications.......................................................... 25

Division 3.3—Application procedure including prior notice                 26

3.10....... Prior notice of pricing applications needed........................................ 26

3.11....... How to apply for pricing services..................................................... 27

3.12....... Notification (including invoicing of fees).......................................... 27

3.13....... Withdrawal........................................................................................ 28

Division 3.4—Validating categories of pricing applications                  30

3.14....... Validating a pricing application’s category........................................ 30

Part 3A—List management services                                                                         31

3A.1...... Fees for providing list management services..................................... 31

3A.2...... How to apply for list management services....................................... 32

3A.3...... Notification (including invoicing of fees).......................................... 32

3A.4...... Withdrawal of a list management application.................................... 33

Part 4—Fees: common rules and independent review fee                          34

4.1......... Payment of fees................................................................................. 34

4.2......... Delay in paying a fee......................................................................... 35

4.3......... Independent review fee..................................................................... 35

4.7......... Indexation of fees.............................................................................. 36

Part 5—Exemptions and waivers                                                                               37

5.1......... Exemptions....................................................................................... 37

5.2......... Waiver of fees................................................................................... 38

Part 6—Review of decisions                                                                                          40

6.1A...... Reviewable decisions........................................................................ 40

6.1......... Notice of review rights...................................................................... 40

6.2......... Internal review.................................................................................. 40

6.3......... Internal review—Secretary................................................................ 42

6.4......... Notice of fee adjustment.................................................................... 42

6.5......... Review by the Administrative Appeals Tribunal............................... 42

Part 7—Application and transitional provisions                                               43

7.1......... Application of these Regulations....................................................... 43

7.2......... Application and transitional provisions for the National Health (Pharmaceuticals and Vaccines—Cost Recovery) Amendment Regulations 2019.......................................... 43

Schedule 1—Applications                                                                                    45

Part 1—Vaccines                                                                                                                  45

Part 2—Pharmaceuticals                                                                                                 46

Part 3—Existing pharmaceutical items                                                                   48

Schedule 2—Medicinal preparations                                                      49

Endnotes                                                                                                                                    50

Endnote 1—About the endnotes                                                                            50

Endnote 2—Abbreviation key                                                                                51

Endnote 3—Legislation history                                                                             52

Endnote 4—Amendment history                                                                           53

 


Part 1Preliminary

  

1.1  Name of Regulations

                   These Regulations are the National Health (Pharmaceuticals and Vaccines—Cost Recovery) Regulations 2009.

1.3  Definitions

                   In these Regulations:

Act means the National Health Act 1953.

amount includes a nil amount.

ATAGI means the Commonwealth acting through the Australian Technical Advisory Group on Immunisation.

ATAGI advice has the meaning given by subregulation 1A.1(1).

ATAGI application means an application under Division 1A.1.

Australian Register of Therapeutic Goods has the same meaning as in the Therapeutic Goods Act 1989.

brand has the meaning given by subsection 84 (1) of the Act.

Committee means the Commonwealth acting through the Pharmaceutical Benefits Advisory Committee.

designated orphan drug has the same meaning as in the Therapeutic Goods Regulations 1990.

economic evaluation, for an application under Part 2 and a drug, medicinal preparation or vaccine the subject of the application (the proposed drug or vaccine), means data that is a comparative analysis of the costs and outcomes of:

                     (a)  the therapy to be provided by the proposed drug or vaccine; and

                     (b)  any other therapy that the applicant nominates as an alternative therapy to the proposed drug or vaccine.

listed brand has the meaning given by subsection 84 (1) of the Act.

listed drug has the meaning given by subsection 84 (1) of the Act.

list management application means an application under Part 3A.

list management services means services provided as described in regulation 3A.1.

medicinal food means food that is a therapeutic good within the meaning of paragraphs (a) and (b) of the definition of therapeutic goods in section 3 of the Therapeutic Goods Act 1989.

meeting application means an application under Division 1A.2.

notification, for an application, means a notification given under:

                     (a)  for an ATAGI application—regulation 1A.4; or

                     (b)  for a meeting application—regulation 1A.10; or

                     (c)  for an application under Part 2 for which prior notice is required under subregulation 2.15(1)—subregulation 2.17(1) about the prior notice of the application; or

                     (d)  for an application under Part 2 for which prior notice is not required under subregulation 2.15(1)—subregulation 2.17(2); or

                     (e)  for a pricing application for which prior notice is given as described in paragraph 3.10(1)(a)—subregulation 3.12(1) about the prior notice of the pricing application; or

                      (f)  for a pricing application for which prior notice is not given as described in paragraph 3.10(1)(a)—subregulation 3.12(2); or

                     (g)  for a list management application—regulation 3A.3.

Part 2 submission means a submission referred to in subregulation 2.1(1).

pharmaceutical item has the meaning given by section 84AB of the Act.

pricing application means an application under Part 3.

pricing services means services provided as described in subregulation 3.2(1).

Secretary has the meaning given by subsection 4 (1) of the Act.

submission due day has the meaning given by subregulation 2.16(3).

submission services means services provided as described in subregulation 2.2(1).

therapy, for an application under these Regulations, means the clinical purpose stated in the application for a drug, medicinal preparation or vaccine.

usual ATAGI fee has the meaning given by subregulation 1A.1(2).

Part 1APre‑submission services

Division 1A.1Providing ATAGI advice

1A.1  Fees for providing ATAGI advice

             (1)  On or after 1 July 2020, a person may make an application (the ATAGI application) for the provision of advice (the ATAGI advice) by ATAGI to the person for the person to include in a proposed Part 2 submission to the Committee that the Committee recommend to the Minister that the Minister exercise a power under section 9B of the Act.

             (2)  For the purposes of section 99YBA of the Act, the fee (the usual ATAGI fee) prescribed for providing the ATAGI advice to the person is $300,440 (if the notification for the person’s ATAGI application is given during the financial year starting on 1 July 2020).

Note:          This fee is indexed for later financial years (see regulation 4.7).

1A.2  Partial exemption from usual ATAGI fee for simple ATAGI applications

Person may be partially exempt from usual ATAGI fee

             (1)  The Secretary may, in writing and on request, decide whether or not to partially exempt a person from the usual ATAGI fee.

Note 1:       A decision not to partially exempt a person is reviewable (see regulation 6.1A).

Note 2:       Regardless of this regulation, in some circumstances the person will be fully exempt from the usual ATAGI fee (see regulation 5.1).

             (2)  The Secretary must decide under subregulation (1) to partially exempt the person if:

                     (a)  the person’s ATAGI application is only proposing:

                              (i)  that a new brand of vaccine be determined under subsection 9B(2) of the Act as a designated vaccine; and

                             (ii)  that the proposed determination is to specify the vaccine by reference to characteristics (other than brand) that are the same as or similar to those specified for another vaccine that is already a designated vaccine; or

                     (b)  the person’s ATAGI application is only proposing:

                              (i)  to vary the circumstances specified in a determination under subsection 9B(2) of the Act in which a designated vaccine may be provided; and

                             (ii)  that the variation is to extend the vaccine’s eligible patient population to a new group of patients who are no more vulnerable to a poor outcome from either the relevant disease or the vaccine; or

                     (c)  the Secretary is satisfied that providing the ATAGI advice to the person will not involve the degree of data analysis and consideration that would justify payment of the entire usual ATAGI fee.

For the purposes of paragraph (a), brand has the same meaning as in section 9B of the Act.

Note:          For examples of the characteristics referred to in subparagraph (a)(ii), see subsection 9B(3) of the Act.

Fee payable if a person is partially exempt

             (3)  If a person is partially exempt under subregulation (1), the fee for providing the ATAGI advice to the person is reduced. The reduced fee is $178,550 (if the notification for the person’s ATAGI application is given during the financial year starting on 1 July 2020).

Note:          This reduced fee is indexed for later financial years (see regulation 4.7).

ATAGI application must indicate if partial exemption is requested

             (4)  A person who wants the Secretary to make a decision under subregulation (1) must request this in the person’s ATAGI application, and include reasons in the ATAGI application why the Secretary should do so.

             (5)  The Secretary may, by written notice given to the applicant, seek further information from the applicant in relation to the applicant’s request.

             (6)  Giving such a notice seeking further information pauses the 21‑day period mentioned in subregulation 1A.4(1) for the ATAGI application until the further information is given in accordance with the notice.

1A.3  How to make an ATAGI application

             (1)  An ATAGI application must:

                     (a)  be made in writing, in the approved form, to the Secretary; and

                     (b)  be sent to the office of the Department administering ATAGI.

Note:          The address for the office administering ATAGI can be found on the Department’s website.

             (2)  The Secretary may, in writing, approve a form for use in making ATAGI applications.

1A.4  Notification (including invoicing of fees)

             (1)  Within 21 days after the day the Department receives an ATAGI application, the Secretary must notify the applicant in writing:

                     (a)  that the Department has received the application; and

                     (b)  if the applicant requests a fee exemption under regulation 1A.2 or 5.1:

                              (i)  whether the fee exemption applies; and

                             (ii)  for a request under regulation 1A.2—of the applicant’s review rights under Part 6; and

                     (c)  of the amount of the fee that is payable for the service of ATAGI providing advice in response to the application; and

                     (d)  of the manner for paying that fee.

             (2)  The fee for the service is payable to the Department unless a fee exemption applies under regulation 5.1.

Note 1:       If a fee exemption under regulation 1A.2 applies, the reduced fee referred to in paragraph (1)(c) (and subregulation 1A.2(3)) is payable.

Note 2:       Part 4 deals with the payment of fees, including the time for payment (see paragraph 4.1(1)(b)).

1A.5  Withdrawal of an ATAGI application

             (1)  An ATAGI application may be withdrawn by written notice to the Department.

             (2)  If the ATAGI application is withdrawn within 14 days after the day notice about the application is given under regulation 1A.4, the Department must refund any fee paid for the service of ATAGI providing advice in response to the application.

1A.6  Resending ATAGI applications

             (1)  An applicant for an ATAGI application may remake and resend the ATAGI application in the same or an amended form.

Example:    An applicant responds to an ATAGI advice by amending, and resending, the ATAGI application with the aim of receiving different ATAGI advice.

             (2)  These Regulations apply to the resent application as if it were a new application.

Note:          This means, for example, that the resent application will attract a new fee under regulation 1A.1.

Division 1A.2Holding pre‑submission meetings

1A.7  Fees for holding pre‑submission meetings

                   For the purposes of section 99YBA of the Act, the following fee is prescribed for the service of the Department holding a pre‑submission meeting with a person:

                     (a)  in response to an application (the meeting application) by the person; and

                     (b)  in relation to the preparation of the person’s proposed Part 2 submission to the Committee that the Committee recommend to, or advise, the Minister that the Minister exercise a power mentioned in an item in Schedule 1.

 

Fee for providing the service of holding a pre‑submission meeting

Item

Category of pre‑submission meeting to be held

Fee if the notification for the application is given during the financial year starting on 1 July 2019

Fee if the notification for the application is given during the financial year starting on 1 July 2020

1

First meeting

$16,090

$16,290

2

Second or a subsequent meeting

$21,090

$21,360

Note:          These fees are indexed for later financial years (see regulation 4.7).

1A.8  How to apply for a pre‑submission meeting

             (1)  A meeting application, and briefing papers for the meeting, must:

                     (a)  be made in writing, in the approved form, to the Secretary; and

                     (b)  be sent to the office of the Department arranging such meetings.

Note 1:       The briefing papers could be provided with the meeting application or afterwards.

Note 2:       The address for the office arranging pre‑submission meetings can be found on the Department’s website.

             (2)  The Secretary may, in writing, approve forms for:

                     (a)  meeting applications; or

                     (b)  briefing papers for pre‑submission meetings.

1A.9  Agreeing to hold a pre‑submission meeting

                   The Secretary may, in writing, after considering a meeting application and briefing papers for a pre‑submission meeting, agree or not agree to the Department holding the pre‑submission meeting with the applicant.

1A.10  Notification (including invoicing of fees)

             (1)  Within 14 days after the day the Department receives both a meeting application and briefing papers for a pre‑submission meeting, the Secretary must notify the applicant in writing:

                     (a)  that the Department has received the application and briefing papers; and

                     (b)  whether the Secretary agrees under regulation 1A.9 to the Department holding a pre‑submission meeting with the applicant.

             (2)  If the Secretary agrees to the Department holding a pre‑submission meeting with the applicant, the notice under subregulation (1) must also state:

                     (a)  the category of the pre‑submission meeting; and

                     (b)  the amount of the fee that is payable for the service of holding the pre‑submission meeting; and

                     (c)  the manner for paying that fee.

             (3)  The fee for the service is payable to the Department.

Note:          Part 4 deals with the payment of fees, including the time for payment (see paragraph 4.1(1)(b)).

1A.11  Withdrawal of a meeting application

             (1)  A meeting application may be withdrawn by written notice to the Department.

             (2)  If the meeting application is withdrawn before the earlier of:

                     (a)  the 15th day after the day notice about the application and briefing papers is given under regulation 1A.10; and

                     (b)  the last business day before the day the pre‑submission meeting relating to the application is to be held;

the Department must refund any fee paid for the service of holding the pre‑submission meeting.

1A.12  Resending meeting applications

             (1)  An applicant for a meeting application may remake and resend the meeting application in the same or an amended form.

             (2)  These Regulations apply to the resent application as if it were a new application.

Note:          This means, for example, that the resent application will attract a new fee under regulation 1A.7.

Part 2Submission services

Division 2.1APreliminary

2.1A  Simplified outline of this Part

Submission services are provided in response to a person’s submission to the Committee or Minister (also known as an application for those services). The amount of the fee payable for providing the submission services depends on the evaluation category of the person’s application.

If the person’s application is to the Committee, and is in the major or minor evaluation category, the person will need to have given the Department prior notice at least 28 days before the day the Committee requires applications for the relevant Committee meeting that will be considering the application. The day that the Committee requires applications will be different depending on the evaluation category of the person’s application.

This prior notice must include the evaluation category that the application is likely to be in. The person will generally be invoiced a fee for the submission services that reflects this evaluation category.

If the Secretary later decides that the application is in a different evaluation category, the person will be notified and any difference in the fee payable will be refunded or invoiced as appropriate.

Submission services will not be provided in response to the person’s application if this prior notice is not given. The only exception to this is if the Secretary is satisfied that prior notice is not required because the submission services are required to address an urgent public health need.

Division 2.1Submissions to the Committee or Minister etc.

Subdivision 1Fees and associated applications

2.1  Which submissions (also known as applications for services) are relevant?

             (1)  A person may prepare a submission (the application):

                     (a)  that includes a request that the Committee recommends to, or advises, the Minister that the Minister exercise a power mentioned in an item in Schedule 1; or

                     (b)  for the Minister to exercise a power mentioned in an item of Part 3 of Schedule 1.

             (2)  An application may include more than one request relating to the exercise of a power mentioned in an item of Part 1 or 2 of Schedule 1, but only if:

                     (a)  each of the requests relates to the same drug, medicinal preparation or vaccine; or

                     (b)  the application proposes therapy for a disease or disorder and each of the requests relates to the same disease or disorder that is the subject of the proposed therapy.

Note:          For details about how to apply, see regulation 2.16.

2.2  Fees for submission services

             (1)  For the purposes of section 99YBA of the Act, the following fees are prescribed:

                     (a)  a fee for the services provided by the Committee in considering whether to make the recommendation, or give the advice, referred to in paragraph 2.1(1)(a);

                     (b)  a fee for the services provided by the Commonwealth in assisting the Minister to consider whether to exercise the power referred to in paragraph 2.1(1)(b).

 

Fee for providing submission services

Item

Submission services provided in response to an application in this evaluation category:

Fee if the notification for the application is given during the financial year starting on 1 July 2019

Fee if the notification for the application is given during the financial year starting on 1 July 2020

1

Major

$179,510

$225,180

2

Minor, otherwise than because of regulation 2.9

$27,310

$40,470

3

Minor, because of regulation 2.9

$26,920

$40,070

4

Committee secretariat

$5,940

$10,880

5

New brand of existing pharmaceutical item

$2,910

$5,320

             (2)  Each of the fees in items 1 and 2 of the table includes a deposit of:

                     (a)  if the notification for the application is given during the financial year starting on 1 July 2019—$390; or

                     (b)  if the notification for the application is given during the financial year starting on 1 July 2020—$400.

Note:          These fees and deposits are indexed for later financial years (see regulation 4.7).

Subdivision 2Applications that are major

2.3  Major—applications to list

                   An application is in the major category if it includes a request for the Committee to recommend to the Minister that the Minister exercise a power mentioned in item 1.1, 1.3, 2.1, 2.3, or 2.10 in Schedule 1.

2.4  Major—health advantage test

             (1)  An application is in the major category if:

                     (a)  it includes a request for the Committee:

                              (i)  to recommend to the Minister that the Minister exercise a power mentioned in item 1.2, 2.2, 2.5 or 2.5A in Schedule 1; or

                             (ii)  to advise the Minister in relation to a power mentioned in item 2.15 in Schedule 1; and

                     (b)  subregulation (2) applies to the request.

             (2)  For subregulation (1), this subregulation applies if the request requires the Committee to assess:

                     (a)  the extent of improvement in efficacy or reduction of toxicity of the therapy proposed in the application compared with therapy provided by any listed drug or designated vaccine; and

                     (b)  the cost of the therapy proposed in the application compared with the cost of the other therapy; and

                     (c)  the additional benefit, described in paragraph (a), in relation to the additional cost of providing the therapy proposed in the application.

2.5  Applications excluded from major category

                   An application that includes a request to which regulation 2.3 or 2.4 applies is not in the major category if regulation 2.10 or 2.11 applies to it.

2.6  Requirements for major applications

                   An application to which regulation 2.3 or 2.4 applies must be supported by an economic evaluation.

Subdivision 3Applications that are minor

2.7  Minor—applications to change listings

             (1)  An application is in the minor category if:

                     (a)  the application is not a major application under Subdivision 2; and

                     (b)  it includes a request for the Committee to advise the Minister in relation to a power mentioned in item 2.15 in Schedule 1.

             (2)  An application is in the minor category if:

                     (a)  it includes a request for the Committee:

                              (i)  to recommend to the Minister that the Minister exercise a power mentioned in item 1.4, 2.4, 2.6, 2.8, 2.9 or 2.11 in Schedule 1; or

                             (ii)  to advise the Minister in relation to a power mentioned in item 2.16 in Schedule 1; and

                     (b)  if the application includes any other request—the application is not a major application under Subdivision 2.

2.8  Minor—clinical need and effectiveness test

             (1)  An application that includes a request for the Committee to recommend to the Minister that the Minister exercise a power mentioned in item 1.2, 2.2, 2.5 or 2.5A in Schedule 1 is in the minor category if:

                     (a)  the application is not a major application under Subdivision 2; and

                     (b)  subregulation (2) applies to the request.

             (2)  For subregulation (1), this subregulation applies if:

                     (a)  the request requires the Committee to assess an applicant’s claim about the clinical need and clinical effectiveness of a request in the application; and

                     (b)  the request does not:

                              (i)  propose any changes to the unit price of a listed drug or designated vaccine; or

                             (ii)  require the Committee to assess any cost implications for the supply of a drug, medicinal preparation or vaccine arising from a request.

2.9  Minor—exceptions to new brand of existing pharmaceutical item category

                   An application for the Minister to exercise a power mentioned in item 3.1 in Schedule 1 is in the minor category if:

                     (a)  the application is about a kind of medicinal preparation mentioned in item 1 of the table in Schedule 2; and

                     (b)  the applicant makes a claim about the therapeutic benefit that would be derived from the relationship between ingredients in the proposed medicinal preparation.

2.10  Minor—applications that are resubmissions

                   An application is in the minor category if:

                     (a)  it is resent under regulation 2.19; and

                     (b)  it was previously in the major category; and

                     (c)  it does not include, in support of a request that was previously considered by the Committee, data that is:

                              (i)  a reconstruction of a modelled economic evaluation previously considered by the Committee; or

                             (ii)  a new methodological basis to support a variable in a modelled economic evaluation previously considered by the Committee; and

                     (d)  the request satisfies the requirements for a major application under a provision in Subdivision 2; and

                     (e)  if it includes a request that was not previously considered by the Committee—that request does not satisfy the requirements for a major application under a provision in Subdivision 2.

2.11  Minor—medicinal foods

                   An application is in the minor category if:

                     (a)  it includes a request that satisfies the requirements for a major application under a provision in Subdivision 2; and

                     (b)  the request relates to a drug or medicinal preparation that is a medicinal food; and

                     (c)  it is not possible for the applicant to comply with the requirement under regulation 2.6 to provide an economic evaluation because the patient population is too small; and

                     (d)  no other request in the application:

                              (i)  relates to a drug or medicinal preparation that is not a medicinal food; and

                             (ii)  meets the criteria for a major application under a provision in Subdivision 2.

Subdivision 4Other categories

2.12  Applications that are Committee Secretariat

             (1)  An application is in the Committee Secretariat category if:

                     (a)  it is an application for the Committee to recommend to the Minister that the Minister exercise a power mentioned in item 2.7 in Schedule 1; and

                     (b)  if the application includes any other request—the application is neither a minor nor a major application under Subdivision 2 or 3.

             (2)  An application that includes a request for the Committee to recommend to the Minister that the Minister exercise a power mentioned in item 1.2, 2.2, 2.5 or 2.5A in Schedule 1 is in the Committee Secretariat category if:

                     (a)  the application demonstrates that the risk to a patient, associated with using a drug, medicinal preparation or vaccine, is not greater than the risk of using a listed drug or a designated vaccine; and

                     (b)  the application is neither a minor nor a major application under Subdivision 2 or 3.

2.13  Committee Secretariat—exceptions to new brand of existing pharmaceutical item category

                   An application for the Minister to exercise a power mentioned in item 3.1 in Schedule 1 is in the Committee Secretariat category if the application is about a kind of medicinal preparation mentioned in item 2 of the table in Schedule 2.

2.14  Applications that are new brand of existing pharmaceutical item

                   An application for the Minister to exercise a power mentioned in item 3.1 in Schedule 1 is in the new brand of existing pharmaceutical item category if the application is not about a kind of medicinal preparation mentioned in Schedule 2.

Division 2.2Application procedure including prior notice

2.15  Prior notice needed for major or minor applications to the Committee

Prior notice required

             (1)  A person proposing to make and send an application in an evaluation category in item 1 or 2 of the table in subregulation 2.2(1) must give the Department prior notice of the application:

                     (a)  in accordance with subregulation (5); and

                     (b)  at least 28 days before the application’s submission due day.

Note 1:       Requiring this prior notice allows the Commonwealth to properly prepare for the provision of submission services in response to the application.

Note 2:       The application will need to be sent to the Department on or before this submission due day (see paragraph 2.16(1)(c)).

Exception if an urgent public health need

             (2)  However, prior notice of the application is not required under subregulation (1) if the Secretary decides under subregulation (3) that providing submission services in response to the application is required to address an urgent public health need.

             (3)  The Secretary may, in writing, decide whether or not providing submission services in response to the application is required to address an urgent public health need.

Note:          A decision that providing the submission services is not required to address an urgent public health need is reviewable (see regulation 6.1A).

Consequence if prior notice is required but not given

             (4)  Submission services will not be provided in response to an application if prior notice of the application:

                     (a)  is required under subregulation (1); and

                     (b)  is not given in accordance with that subregulation.

How to provide prior notice

             (5)  A prior notice under subregulation (1) must:

                     (a)  be made in writing, in the approved form, to the Secretary; and

                     (b)  state, with reasons, why the proposed application is likely to be in a particular evaluation category; and

                     (c)  be sent to the office of the Department administering the Committee.

Note:          The address for the office administering the Committee can be found on the Department’s website.

             (6)  The Secretary may, in writing, approve forms for use in giving a prior notice under subregulation (1) of an application under this Part.

2.16  How to apply for submission services

Procedural requirements for applications

             (1)  An application under this Part must:

                     (a)  be made in writing, in the approved form, to the Secretary; and

                     (b)  if prior notice of the application is not required under subregulation 2.15(1)—state, with reasons, why the application is likely to be in a particular evaluation category; and

                     (c)  be sent, on or before the application’s submission due day (if any), to:

                              (i)  for an application that is likely to be in an evaluation category because of regulation 2.9, 2.13 or 2.14—the office of the Department administering applications about item 3.1 in Schedule 1; or

                             (ii)  otherwise—the office of the Department administering the Committee.

Note:          The addresses for the offices mentioned in paragraph (c) can be found on the Department’s website.

             (2)  The Secretary may, in writing, approve forms for use in making applications under this Part.

Submission due day

             (3)  For an application under this Part that:

                     (a)  is for the Committee; and

                     (b)  is likely to be in a particular evaluation category;

the submission due day is the day by which the Committee needs to have received applications in that evaluation category for the Committee meeting that is to consider the application.

Note:          The submission due day for applications in one evaluation category could be different from that for applications in another evaluation category.

             (4)  The Secretary must ensure that the submission due days for future Committee meetings are published on the Department’s website.

2.17  Notification (including invoicing of fees)

Notices relating to proposed major or minor applications for the Committee

             (1)  Within 14 days after the day the Department receives a notice under subregulation 2.15(1) from a person about a proposed application, the Secretary must notify the person in writing:

                     (a)  that the Department has received the notice; and

                     (b)  based on the statement in the notice about the evaluation category of the proposed application—of the amount of the fee that is payable for providing submission services in response to the proposed application; and

                     (c)  of the manner for paying that fee.

The fee for the submission services is payable to the Department.

Note 1:       The fee must be paid within a period starting when this notification is given (see paragraph 4.1(1)(b)).

Note 2:       For the table in subregulation 2.2(1), the financial year for working out the fee is the financial year in which this notification is given (see paragraph (c) of the definition of notification in regulation 1.3).

Note 3:       If it is later found that a fee exemption or waiver under regulation 5.1 or 5.2 applies, a refund may be payable (see subregulation 4.1(4)).

Notices relating to applications

             (2)  Within 21 days after the day the Department receives an application under this Part, the Secretary must notify the applicant in writing:

                     (a)  that the Department has received the application; and

                     (b)  if the applicant requests a fee exemption or waiver under regulation 5.1 or 5.2:

                              (i)  whether the fee exemption applies, or the fee is waived or partially waived; and

                             (ii)  in relation to a request for a waiver—of the applicant’s review rights under Part 6; and

                     (c)  if prior notice of the application is not required under subregulation 2.15(1):

                              (i)  of the amount of the fee payable for providing submission services in response to the application, worked out based on the statement in the application about its evaluation category; and

                             (ii)  of the manner for paying that fee.

             (3)  If paragraph (2)(c) applies, the fee for the submission services, or any part of the fee that has not been waived, is payable to the Department unless:

                     (a)  a fee exemption applies; or

                     (b)  the fee is waived in its entirety.

Note:          Part 4 deals with the payment of fees, including the time for payment (see paragraph 4.1(1)(b)).

2.18  Withdrawal

Prior notices or applications may be withdrawn at any time

             (1)  Either of the following may be withdrawn by written notice to the Department:

                     (a)  a notice (a prior notice) under subregulation 2.15(1) given about a proposed application;

                     (b)  an application under this Part.

When a withdrawal will result in a refund

             (2)  If the prior notice is withdrawn within 14 days after the day a notification is given under subregulation 2.17(1) about the prior notice, the Department must refund any fee paid for providing submission services in response to the proposed application except for the deposit referred to in subregulation 2.2(2).

             (3)  If all of the following apply:

                     (a)  prior notice of the application is not required under subregulation 2.15(1);

                     (b)  a notification is given under subregulation 2.17(2) about the application;

                     (c)  the application is withdrawn within 14 days after the day that notification is given;

the Department must refund any fee paid for providing submission services in response to the application.

2.19  Resending applications

             (1)  An applicant for an application under this Part may remake and resend the application in the same or an amended form. These Regulations apply to the resent application as if it were a new application.

Note:          This means, for example, that the resent application will attract a new fee under regulation 2.2.

             (2)  Despite subregulation (1) and regulation 2.15, prior notice under subregulation 2.15(1) of the resent application is not required if the Secretary agrees to this under subregulation (3) of this regulation.

Note:          Prior notice will also not be required if the resent application is in one of the evaluation categories in items 3 to 5 of the table in subregulation 2.2(1).

             (3)  The Secretary may, by written notice given to the applicant, agree that prior notice under subregulation 2.15(1) of the resent application is not required if the Secretary is satisfied that:

                     (a)  the absence of prior notice would not unduly affect the provision of submission services in response to the resent application; and

                     (b)  the resent application would be in the minor category (see Subdivision 3 of Division 2.1) for consideration at the next meeting of the Committee.

Division 2.3Validating evaluation categories and assessing applications

2.20  Validating an application’s evaluation category

             (1)  After having:

                     (a)  had regard to the matters in Division 2.1; and

                     (b)  consulted with the Chair of the Committee;

the Secretary may, in writing, determine that an application under this Part is in one of the evaluation categories mentioned in that Division.

Note:          The Secretary may initiate a review of the decision to make the determination (see regulation 6.3).

             (2)  If the evaluation category determined under subregulation (1) for the application is different from the evaluation category used to work out the fee notified to the person under regulation 2.17 (or previously under this regulation), the Secretary must notify the person in writing accordingly.

             (3)  A notice under subregulation (2) to the person must state:

                     (a)  the amounts of the fees payable for the submission services that relate to each of those evaluation categories; and

                     (b)  the fee amounts already paid, or refunded, (if any) for the submission services; and

                     (c)  the fee amount that is to be refunded to, or is payable by, the person that reflects the amounts referred to in paragraphs (a) and (b); and

                     (d)  the manner for paying any amount referred to in paragraph (c) that is payable by the person; and

                     (e)  the applicant’s review rights under Part 6 in relation to the determination under subregulation (1).

Any fee amount notified under paragraph (c) as being payable is payable to the Department.

Note:          Part 4 deals with the payment of fees, including the time for payment (see paragraph 4.1(1)(b)).

             (4)  For the purposes of paragraph (3)(a), the fee payable for the submission services that relates to the new evaluation category determined under subregulation (1) is worked out as if that fee had been notified to the person during the same financial year as that in which the notification for the application was given to the person.

2.21  Assessing applications

             (1)  The Committee or the Minister may request further information from the applicant about an application under this Part.

             (2)  If the Committee, or the Minister, (the assessor) is unable to assess such an application without further information, the assessor may ask the Secretary to consider:

                     (a)  making a determination under subregulation 2.20(1) about the application; or

                     (b)  reviewing under regulation 6.3 a determination under subregulation 2.20(1), or a decision under subregulation 5.2(1), about the application.

Part 3Pricing services

Division 3.1Preliminary

3.1  Simplified outline of this Part

Pricing services may be sought after a meeting of the Committee that results in the Committee making a positive recommendation, or giving positive advice, as part of providing submission services under Part 2.

The pricing services will be provided in response to a person’s pricing application. The amount of the fee payable for providing the pricing services depends on the category of the person’s pricing application.

The person will need to have given the Department at least 7 days prior notice of the pricing application.

This prior notice must include the category that the pricing application is likely to be in. The person will generally be invoiced a fee for the pricing services that reflects this category.

If the Secretary later decides that the pricing application is in a different category, the person will be notified and any difference in the fee payable will be refunded or invoiced as appropriate.

Pricing services will be delayed if this prior notice is not given. The only exception to this is if the Secretary is satisfied that prior notice is not required because the pricing services are required to address an urgent public health need.

The pricing application will need to be sent to the Department within 42 days after this prior notice is given.

Division 3.2Fees and associated applications

3.2  Applications for pricing services

             (1)  A person may apply (the pricing application) for the Commonwealth to provide services (pricing services) in assisting the Minister to consider whether to exercise one or more powers under section 85AD, 85B or 85E of the Act in relation to one or more drugs or medicinal preparations.

Note:          For details about how to apply, see regulation 3.11.

             (2)  However, the person may only make the pricing application if the Committee has made a positive recommendation, or given positive advice, in response to a single Part 2 submission made to the Committee by the person that covers all of those drugs or medicinal preparations.

Note 1:       A single submission can only cover multiple drugs or medicinal preparations in the case set out in paragraph 2.1(2)(b).

Note 2:       A separate pricing application is required for a drug or medicinal preparation covered by a separate submission to the Committee. This means separate fees under regulation 3.3 are payable for providing pricing services relating to the drugs or medicinal preparations covered by separate submissions to the Committee.

3.3  Fees for providing pricing services

             (1)  For the purposes of section 99YBA of the Act, the following fee is prescribed for the pricing services provided by the Commonwealth in response to the pricing application.

 

Fee for providing pricing services

Item

Pricing services provided in response to this category of pricing application:

Fee if the notification for the application is given during the financial year starting on 1 July 2019

Fee if the notification for the application is given during the financial year starting on 1 July 2020

1

Pricing Pathway A

$119,310

$120,810

2

Pricing Pathway B

$92,530

$93,700

3

Pricing Pathway C

$58,180

$58,920

4

Pricing Pathway D

$13,550

$19,910

5

Pricing Secretariat

$6,140

$10,890

             (2)  Each of these fees includes a deposit of:

                     (a)  if the notification for the pricing application is given during the financial year starting on 1 July 2019—$390; or

                     (b)  if the notification for the pricing application is given during the financial year starting on 1 July 2020—$400.

Note:          These fees and deposits are indexed for later financial years (see regulation 4.7).

3.4  Pricing Pathway A applications

                   A person’s pricing application is in the Pricing Pathway A category if:

                     (a)  as part of the Committee’s recommendation or advice responding to the person’s Part 2 submission covering the drugs or medicinal preparations to which the pricing application relates, the Committee finds that:

                              (i)  the drugs or medicinal preparations are expected to provide a substantial and clinically relevant improvement in efficacy, or reduction of toxicity, over any alternative therapy; and

                             (ii)  the drugs or medicinal preparations address a high and urgent unmet clinical need; and

                            (iii)  it would be in the public interest for a pricing application relating to the drugs or medicinal preparations to be in this category; and

                     (b)  the pricing application states that the application is to be in this category.

Note:          Prior notice of the pricing application will also need to state that the pricing application is to be in this category (see subregulation 3.10(5)).

3.5  Pricing Pathway B applications

             (1)  A person’s pricing application is in the Pricing Pathway B category if:

                     (a)  the pricing application seeks the entering into of a deed under section 85E of the Act for the drugs or medicinal preparations to which the pricing application relates (the new drugs); and

                     (b)  no deed under that section is in force (between the Commonwealth and any person) that contains terms about the following (the pricing terms):

                              (i)  reimbursing the Commonwealth;

                             (ii)  providing the Commonwealth with information;

                            that are substantially similar to those appropriate for the new drugs; and

                     (c)  the pricing application is not in the Pricing Pathway A category.

Note:          Regulation 3.7 is relevant to paragraph (b).

             (2)  For the purposes of paragraph (1)(b), the pricing terms will be appropriate for the new drugs if they are consistent with the Committee’s recommendation or advice responding to the person’s Part 2 submission covering the new drugs.

3.6  Pricing Pathway C applications

             (1)  A person’s pricing application is in the Pricing Pathway C category if:

                     (a)  the pricing application seeks the entering into of a deed under section 85E of the Act for the drugs or medicinal preparations to which the pricing application relates (the new drugs); and

                     (b)  a deed under that section is in force (between the Commonwealth and any person) that contains terms about the following (the pricing terms):

                              (i)  reimbursing the Commonwealth;

                             (ii)  providing the Commonwealth with information;

                            that are substantially similar to those appropriate for the new drugs; and

                     (c)  the pricing application is not in the Pricing Pathway A category.

Note:          Regulation 3.7 is relevant to paragraph (b).

             (2)  For the purposes of paragraph (1)(b), the pricing terms will be appropriate for the new drugs if they are consistent with the Committee’s recommendation or advice responding to the person’s Part 2 submission covering the new drugs.

3.7  When pricing terms are substantially similar to those appropriate for the new drugs

             (1)  This regulation applies for the purposes of paragraphs 3.5(1)(b) and 3.6(1)(b).

When terms are substantially similar to those appropriate for the new drugs

             (2)  The pricing terms in an existing deed will be substantially similar to those appropriate for the new drugs if, under those terms, the new drugs can share an existing subsidisation cap with the drugs or medicinal preparations in the existing deed.

             (3)  The pricing terms in an existing deed will be substantially similar to those appropriate for the new drugs if:

                     (a)  the Committee’s recommendation or advice responding to the person’s Part 2 submission covering the new drugs suggested that the pricing terms in the existing deed would be appropriate for the new drugs; and

                     (b)  this suggestion relates to claims in that submission of the kind referred to in subparagraphs 3.8(2)(a)(i), (ii) and (iii).

When terms are not substantially similar to those appropriate for the new drugs

             (4)  Despite subregulations (2) and (3), the pricing terms in an existing deed will not be substantially similar to those appropriate for the new drugs if:

                     (a)  those terms relate to further clinical testing, or to the collection of further clinical data on the effectiveness, of drugs or medicinal preparations; or

                     (b)  those terms, to the extent that they reimburse the Commonwealth, include taking into account the clinical response of patients to drugs or medicinal preparations; or

                     (c)  those terms include an existing subsidisation cap that cannot be shared with the new drugs; or

                     (d)  those terms, to the extent that they reimburse the Commonwealth, relate to Commonwealth expenditure on a therapy that involves using the new drugs in combination with any of the drugs or medicinal preparations covered by the existing deed.

Circumstances in the above subregulations are not exhaustive

             (5)  This regulation does not set out the only circumstances in which the pricing terms in an existing deed will be, or will not be, substantially similar to those appropriate for the new drugs.

3.8  Pricing Pathway D applications

             (1)  A person’s pricing application is in the Pricing Pathway D category if:

                     (a)  subregulation (2), (3), (4) or (5) applies to the pricing application; and

                     (b)  the pricing application does not seek the entering into of a deed under section 85E of the Act for the drugs or medicinal preparations to which the pricing application relates (the new drugs); and

                     (c)  the pricing application is not in the Pricing Pathway A category.

             (2)  This subregulation applies to the pricing application if the pricing application:

                     (a)  notes that the person’s Part 2 submission to the Committee covering the new drugs included one or more of the following claims about the new drugs and an alternative therapy:

                              (i)  a claim that the effectiveness of specified doses of the new drugs is equivalent to specified doses of the alternative therapy;

                             (ii)  a claim that the new drugs will provide similar health benefits to those provided by the alternative therapy;

                            (iii)  a claim that the new drugs may be supplied at the same or a lower price per treatment, or price per unit, as that for the alternative therapy; and

                     (b)  notes that the claims are consistent with the Committee’s recommendation or advice to the Minister responding to that submission; and

                     (c)  suggests a price based on the claims.

             (3)  This subregulation applies to the pricing application if:

                     (a)  the pricing application notes that the person’s Part 2 submission to the Committee covering the new drugs:

                              (i)  claimed that the use of the new drugs provides a significant improvement in the efficacy or reduction in toxicity compared to any alternative therapy; and

                             (ii)  requested for the new drugs a higher price per treatment, or price per unit, than that for an alternative therapy; and

                     (b)  the pricing application requests for the new drugs a higher price per treatment, or price per unit, than that for:

                              (i)  the alternative therapy referred to in subparagraph (a)(ii); or

                             (ii)  another alternative therapy if, as part of the Committee’s recommendation or advice (the Committee’s response) responding to that submission, the Committee finds that the other therapy is clinically comparable to the new drugs; and

                     (c)  the claim in paragraph (a) and the requests in paragraphs (a) and (b) are consistent with the Committee’s response.

             (4)  This subregulation applies to the pricing application if:

                     (a)  the pricing application notes that the person’s Part 2 submission to the Committee covering the new drugs included a request for a review of the existing price for a listed drug; and

                     (b)  the resulting price requested in the pricing application is consistent with the Committee’s recommendation or advice to the Minister responding to that submission.

             (5)  This subregulation applies to the pricing application if:

                     (a)  the pricing application notes that the person’s Part 2 submission to the Committee covering the new drugs included both of the following claims about the new drugs and an alternative therapy:

                              (i)  a claim that the new drugs will provide similar health benefits to those provided by the alternative therapy;

                             (ii)  a claim that the new drugs may be supplied at the same or a lower price per treatment, or price per unit, as that for the alternative therapy; and

                     (b)  the claims are consistent with the Committee’s recommendation or advice to the Minister responding to that submission.

3.9  Pricing Secretariat applications

                   A person’s pricing application is in the Pricing Secretariat category if it is not in the Pricing Pathway A, B, C or D category.

Division 3.3Application procedure including prior notice

3.10  Prior notice of pricing applications needed

Prior notice required

             (1)  A person proposing to make and send a pricing application:

                     (a)  must give the Department prior notice of the pricing application in accordance with subregulation (5); and

                     (b)  must do so at least 7 days before the day the person sends the proposed pricing application to the Department.

Note 1:       Requiring this prior notice allows the Commonwealth to properly prepare for the provision of pricing services in response to the pricing application.

Note 2:       The pricing application will need to be sent to the Department within 42 days after this prior notice is given (see paragraph 3.11(1)(d)).

Exception if an urgent public health need

             (2)  However, prior notice of the pricing application is not required under subregulation (1) if the Secretary decides under subregulation (3) that providing pricing services in response to the pricing application is required to address an urgent public health need.

             (3)  The Secretary may, in writing, decide whether or not providing pricing services in response to the pricing application is required to address an urgent public health need.

Note:          A decision that providing the pricing services is not required to address an urgent public health need is reviewable (see regulation 6.1A).

Consequence if prior notice is required but not given

             (4)  The provision of pricing services in response to a pricing application will be delayed if prior notice of the pricing application:

                     (a)  is required under subregulation (1); and

                     (b)  is not given in accordance with that subregulation.

The pricing services will not begin to be provided until at least 7 days after the day the pricing application is sent to the Department.

How to provide prior notice

             (5)  A prior notice under subregulation (1) must:

                     (a)  be made in writing, in the approved form, to the Secretary; and

                     (b)  state, with reasons, why the proposed pricing application is to be in a particular category; and

                     (c)  be sent to the office of the Department arranging pricing services.

Note:          The address for the office arranging pricing services can be found on the Department’s website.

             (6)  The Secretary may, in writing, approve forms for use in giving a prior notice under subregulation (1) of a pricing application.

3.11  How to apply for pricing services

             (1)  A pricing application must:

                     (a)  be made in writing, in the approved form, to the Secretary; and

                     (b)  if prior notice of the pricing application is not given as described in paragraph 3.10(1)(a)—state, with reasons, why the pricing application is to be in a particular category; and

                     (c)  be sent to the office of the Department arranging pricing services; and

                     (d)  if prior notice of the pricing application is given as described in paragraph 3.10(1)(a)—be sent to that office of the Department within 42 days after the day the prior notice is so given.

Note:          The address for the office arranging pricing services can be found on the Department’s website.

             (2)  If:

                     (a)  prior notice of a proposed pricing application is given as described in paragraph 3.10(1)(a); but

                     (b)  the proposed pricing application is not sent as required under paragraph (1)(d) of this regulation;

the Department must refund any fee paid for providing pricing services in response to the proposed pricing application except for the deposit referred to in subregulation 3.3(2).

Note:          If the person still seeks the pricing services, the person will need to give prior notice again under regulation 3.10 of a new pricing application.

             (3)  The Secretary may, in writing, approve forms for use in making pricing applications.

3.12  Notification (including invoicing of fees)

Notices relating to proposed pricing applications

             (1)  Within 14 days after the day the Department receives a notice as described in paragraph 3.10(1)(a) from a person about a proposed pricing application, the Secretary must notify the person in writing:

                     (a)  that the Department has received the notice; and

                     (b)  based on the statement in the notice about the category of the proposed pricing application—of the amount of the fee that is payable for providing pricing services in response to the proposed pricing application; and

                     (c)  of the manner for paying that fee.

The fee for the pricing services is payable to the Department.

Note 1:       The fee must be paid within a period starting when this notification is given (see paragraph 4.1(1)(b)).

Note 2:       For the table in subregulation 3.3(1), the financial year for working out the fee is the financial year in which this notification is given (see paragraph (e) of the definition of notification in regulation 1.3).

Note 3:       If it is later found that a fee exemption or waiver under regulation 5.1 or 5.2 applies, a refund may be payable (see subregulation 4.1(4)).

Notices relating to pricing applications

             (2)  Within 21 days after the day the Department receives a pricing application, the Secretary must notify the applicant in writing:

                     (a)  that the Department has received the pricing application; and

                     (b)  if the applicant requests a fee exemption or waiver under regulation 5.1 or 5.2:

                              (i)  whether the fee exemption applies, or the fee is waived or partially waived; and

                             (ii)  in relation to a request for a waiver—of the applicant’s review rights under Part 6; and

                     (c)  if prior notice of the pricing application is not given as described in paragraph 3.10(1)(a):

                              (i)  of the amount of the fee payable for providing pricing services in response to the pricing application, worked out based on the statement in the pricing application about its category; and

                             (ii)  of the manner for paying that fee.

             (3)  If paragraph (2)(c) applies, the fee for the pricing services, or any part of the fee that has not been waived, is payable to the Department unless:

                     (a)  a fee exemption applies; or

                     (b)  the fee is waived in its entirety.

Note:          Part 4 deals with the payment of fees, including the time for payment (see paragraph 4.1(1)(b)).

3.13  Withdrawal

Prior notices or pricing applications may be withdrawn at any time

             (1)  Either of the following may be withdrawn by written notice to the Department:

                     (a)  a notice (a prior notice) given as described in paragraph 3.10(1)(a) about a proposed pricing application;

                     (b)  a pricing application.

When a withdrawal will result in a refund

             (2)  If the prior notice is withdrawn within 14 days after the day a notification is given under subregulation 3.12(1) about the prior notice, the Department must refund any fee paid for providing pricing services in response to the proposed pricing application except for the deposit referred to in subregulation 3.3(2).

             (3)  If all of the following apply:

                     (a)  prior notice of the pricing application is not given as described in paragraph 3.10(1)(a);

                     (b)  a notification is given under subregulation 3.12(2) about the pricing application;

                     (c)  the pricing application is withdrawn within 14 days after the day that notification is given;

the Department must refund any fee paid for providing pricing services in response to the pricing application.

Division 3.4Validating categories of pricing applications

3.14  Validating a pricing application’s category

             (1)  After having had regard to the matters in regulations 3.4 to 3.9, the Secretary may, in writing, determine that a pricing application is in one of the categories mentioned in those regulations.

Note:          The Secretary may initiate a review of the decision to make the determination (see regulation 6.3).

             (2)  If the category determined under subregulation (1) for a pricing application is different from the category used to work out the fee notified to the person under regulation 3.12 (or previously under this regulation), the Secretary must notify the person in writing accordingly.

             (3)  A notice under subregulation (2) to the person must state:

                     (a)  the amounts of the fees payable for the pricing services that relate to each of those categories; and

                     (b)  the fee amounts already paid, or refunded, (if any) for the pricing services; and

                     (c)  the fee amount that is to be refunded to, or is payable by, the person that reflects the amounts referred to in paragraphs (a) and (b); and

                     (d)  the manner for paying any amount referred to in paragraph (c) that is payable by the person; and

                     (e)  the applicant’s review rights under Part 6 in relation to the determination under subregulation (1).

Any fee amount notified under paragraph (c) as being payable is payable to the Department.

Note:          Part 4 deals with the payment of fees, including the time for payment (see paragraph 4.1(1)(b)).

             (4)  For the purposes of paragraph (3)(a), the fee payable for the pricing services that relates to the new category determined under subregulation (1) is worked out as if that fee had been notified to the person during the same financial year as that in which the notification for the pricing application was given to the person.

Part 3AList management services

  

3A.1  Fees for providing list management services

             (1)  For the purposes of section 99YBA of the Act, the fee set out in an item of the following table is prescribed for the Commonwealth providing services (the list management services):

                     (a)  in response to an application (the list management application) by a person; and

                     (b)  in assisting the Minister to consider whether to exercise a power under a provision of Part VII of the Act set out in that item of the table.

 

Fee for providing list management services

Item

List management services provided in assisting the Minister exercise a power under this provision of Part VII of the Act:

Fee if the notification for the application for those services is given during the financial year starting on 1 July 2019

Fee if the notification for the application for those services is given during the financial year starting on 1 July 2020

1

(a) subsection 85AD(1) (about price agreements); or

(b) section 85B (about price determinations);

in relation to a listed brand of a pharmaceutical item if subregulation (2) applies.

$2,330

$2,370

2

(a) subsection 99ACB(6A); or

(b) subsection 99ACB(6B); or

(c) subsection 99ACBA(1); or

(d) subsection 99ACD(7A); or

(e) subsection 99ACD(7B); or

(f) subsection 99ACE(5); or

(g) subsection 99ACE(5A); or

(h) subsection 99ACEA(1); or

(i) subsection 99ACF(3); or

(j) subsection 99ACF(3AA); or

(k) subsection 99ACF(3AB).

$3,480

$3,540

Note:          Each of these fees is indexed for later financial years (see regulation 4.7).

             (2)  This subregulation applies if:

                     (a)  either:

                              (i)  a price agreement under section 85AD of the Act is in force between the person and the Minister for the listed brand of the pharmaceutical item; or

                             (ii)  determinations under subsections 85B(2) and (3) of the Act are in force for the listed brand of the pharmaceutical item; and

                     (b)  since that agreement or those determinations entered into force, the Committee has not made a recommendation, or given advice, in response to a Part 2 submission made by the person in relation to:

                              (i)  the listed brand of the pharmaceutical item; or

                             (ii)  the drug in the pharmaceutical item; and

                     (c)  in the list management application, the person is seeking:

                              (i)  through the exercise of the power in subsection 85AD(1) of the Act—an increase in the approved ex‑manufacturer price of the listed brand of the pharmaceutical item; or

                             (ii)  the making of a determination under subsection 85B(3) of the Act, or the increase in a price earlier determined under that subsection, in relation to the listed brand of the pharmaceutical item.

3A.2  How to apply for list management services

             (1)  A list management application must:

                     (a)  be made in writing, in the approved form, to the Secretary; and

                     (b)  be sent to the office of the Department providing those services.

Note:          The address for the office providing those services can be found on the Department’s website.

             (2)  The Secretary may, in writing, approve forms for use in making list management applications.

3A.3  Notification (including invoicing of fees)

             (1)  Within 14 days after the day the Department receives a list management application, the Secretary must notify the applicant in writing:

                     (a)  that the Department has received the application; and

                     (b)  of the Ministerial power in Part VII of the Act to which the list management services relate; and

                     (c)  if the applicant requests a fee exemption or waiver under regulation 5.1 or 5.2:

                              (i)  whether the fee exemption applies, or the fee is waived or partially waived; and

                             (ii)  in relation to a request for a waiver—of the applicant’s review rights under Part 6; and

                     (d)  of the amount of the fee that is payable for providing those services; and

                     (e)  of the manner for paying that fee.

             (2)  The fee for the list management services, or any part of the fee that has not been waived, is payable to the Department unless:

                     (a)  a fee exemption applies; or

                     (b)  the fee is waived in its entirety.

Note:          Part 4 deals with the payment of fees, including the time for payment (see paragraph 4.1(1)(b).

3A.4  Withdrawal of a list management application

             (1)  A list management application may be withdrawn by written notice to the Department.

             (2)  If the application is withdrawn within 14 days after the day notice about the application is given under regulation 3A.3, the Department must refund any fee paid for the provision of list management services relating to the application.

Part 4Fees: common rules and independent review fee

  

4.1  Payment of fees

             (1)  A fee payable under these Regulations for services provided by the Commonwealth in response to an application must be paid:

                     (a)  in full to the Commonwealth; and

                     (b)  before the end of the following period of days starting on the day that the Department gives notice under these Regulations to the applicant that the fee is payable:

                              (i)  if the notice is given under subregulation 2.17(1) about prior notice of a proposed application under Part 2 that, when sent to the Department, includes a request for the Secretary to waive under subregulation 5.2(1) all or part of the fee—42 days;

                             (ii)  if the notice is given under subregulation 3.12(1) about prior notice of a proposed pricing application that, when sent to the Department, includes a request for the Secretary to waive under subregulation 5.2(1) all or part of the fee—42 days;

                            (iii)  otherwise—28 days.

             (2)  However, the Secretary may agree, in writing, to accept payment by instalments.

             (3)  If, because of a decision notified under these Regulations to a person, the person has paid a fee amount under these Regulations that falls short of the amount mentioned in that notice as being payable, the person must pay the Commonwealth an amount equal to the shortfall within:

                     (a)  28 days after the day of that notice; or

                     (b)  a longer period allowed by the Secretary.

Note:          The notice by the Secretary could be, for example:

(a)    a notice relating to a different category determined under subregulation 2.20(1) or 3.14(1); or

(b)    a notice under regulation 6.4 about an underpayment because of a replacement decision made as part of a review under Part 6.

             (4)  If a person pays a fee amount under these Regulations that exceeds the amount notified by the Secretary as being payable, the Commonwealth must refund to the person an amount equal to the excess within 28 days after the later of:

                     (a)  the day of that payment by the person of the fee amount; and

                     (b)  the day of that notice by the Secretary of the amount payable.

Note:          The notice by the Secretary could be, for example:

(a)    a notice relating to a different category determined under subregulation 2.20(1) or 3.14(1); or

(b)    a notice under subregulation 2.17(2) of a decision under subregulation 5.2(1) to waive all or part of the fee; or

(c)    a notice under regulation 6.4 about an overpayment because of a replacement decision made as part of a review under Part 6.

             (5)  This regulation does not apply in relation to a fee mentioned in regulation 4.3.

4.2  Delay in paying a fee

             (1)  If a fee payable under these Regulations by a person is not paid before the time the fee must be paid, the Commonwealth may do either or both of the following until the fee is paid or no longer payable:

                     (a)  refuse to consider any application sent (or to be sent) by the person under these Regulations;

                     (b)  refuse to provide any services relating to such an application.

Note 1:       Paragraph (a) means, for example, that the Committee or ATAGI could refuse to consider the person’s current or future applications under these Regulations until the fee is paid or no longer payable.

Note 2:       The Commonwealth could, instead of or in addition to refusing to do these things, seek to recover the unpaid fee as a debt (see subsection 99YBA(5) of the Act).

             (2)  This regulation does not apply in relation to a fee mentioned in regulation 4.3.

4.3  Independent review fee

             (1)  An applicant may seek an independent review of a decision by the Committee not to make a recommendation that the Minister:

                     (a)  declare a drug or medicinal preparation under subsection 85 (2) of the Act; or

                     (b)  specify further circumstances, requested in an application, in which a prescription for the supply of a pharmaceutical benefit may be written under subsection 85 (7) of the Act.

             (2)  The application must:

                     (a)  be submitted in the form in which it was originally considered by the Committee; and

                     (b)  have been rejected by the Committee in its entirety.

             (3)  For the purposes of section 99YBA of the Act, the fee prescribed for the provision by the Commonwealth of an independent review in response to an application under this regulation is the same as the fee that would be payable under Part 2 for submission services:

                     (a)  provided in response to an application under Part 2 that is in the major evaluation category (see table item 1 in subregulation 2.2(1)); and

                     (b)  for which a notification under that Part is given at the same time as the time the application under this regulation is submitted.

This fee for the independent review must be paid in full to the Commonwealth at the time the application under this regulation is submitted.

Note:          The independent review will not commence until the fee is paid.

             (4)  There is no fee for the Committee to reconsider an application following the independent review.

Note:          See the Independent Review (PBS) website at http://www.independentreviewpbs.gov.au.

4.7  Indexation of fees

             (1)  In this regulation:

CPI number means the All Groups Consumer Price Index number (that is, the weighted average of the 8 Australian capital cities) published by the Australian Statistician.

earlier CPI number, for a financial year, means the CPI number for the last March quarter before the beginning of the financial year.

fee includes:

                     (a)  so much of a fee under Part 2 that is specified by subregulation 2.2(2) to be a deposit; and

                     (b)  so much of a fee under Part 3 that is specified by subregulation 3.3(2) to be a deposit.

latest CPI number, for a financial year, means the CPI number for the last March quarter before the end of the financial year.

relevant financial year means a financial year beginning after 30 June 2021.

             (2)  If, in a relevant financial year, the latest CPI number is greater than the earlier CPI number, a fee under these Regulations is taken to increase, on 1 July of the next financial year, in accordance with the following formula:

                  

             (3)  If a fee increased under subregulation (2) would be an amount of dollars and cents, the amount is to be rounded to the nearest whole dollar and, if the amount to be rounded is 50 cents, the amount is to be rounded down.

Note:          The Department publishes information about fees and their indexation under this regulation on its website at http://www.pbs.gov.au.

Part 5Exemptions and waivers

  

5.1  Exemptions

Exemptions for services

             (1)  No fee is payable under these Regulations for services if the application for the services relates to, or is for, any of the following matters:

                     (b)  a drug that is exempt from entry in the Australian Register of Therapeutic Goods because of an approval granted under section 19A of the Therapeutic Goods Act 1989;

                     (c)  if the Secretary considers that the supply of a drug, medicinal preparation or vaccine is necessary for the management of:

                              (i)  a public health event of national significance; or

                             (ii)  a biosecurity emergency that is declared to exist under subsection 443(1) of the Biosecurity Act 2015; or

                            (iii)  a human biosecurity emergency that is declared to exist under subsection 475(1) of the Biosecurity Act 2015;

                     (d)  to offer a price reduction;

                     (e)  to change the name of the responsible person;

                      (f)  to revoke a determination under subsection 9B (2) of the Act;

                     (g)  to vary a determination under subsection 9B (2) of the Act so that a vaccine ceases to be a designated vaccine;

                     (h)  to revoke a declaration under subsection 101 (4AAA) of the Act;

                      (i)  to vary a declaration under subsection 101 (4AAA) of the Act so that a drug or medicinal preparation ceases to be a listed drug;

                      (j)  to revoke an arrangement under subsection 100 (2) of the Act;

                     (k)  to vary an arrangement under section 100 of the Act so that a drug or medicinal preparation ceases to be covered by the arrangement;

                      (l)  to change the pack size with no price implications under section 85AD of the Act;

                    (m)  to vary a declaration, determination, arrangement or other legislative instrument made under Part VII or section 9B of the Act:

                              (i)  at the request of the Human Services Department or the Therapeutic Goods Administration; or

                             (ii)  that is a mandated change because of a Government initiative.

Note:          public health event of national significance is defined in section 3 of the National Health Security Act 2007.

             (2)  Subregulation (1) does not apply in relation to:

                     (a)  services under Division 1A.2 (about pre‑submission meetings); or

                     (b)  services under regulation 4.3 (about independent reviews).

Exemption for submission services relating to designated orphan drugs

             (3)  No fee is payable under these Regulations for submission services provided in response to a person’s application under Part 2 proposing a therapy involving the use of one or more drugs or medicinal preparations if:

                     (a)  on the day the application is sent to the Department under Part 2, subregulation (4) applies to each of those drugs or medicinal preparations; and

                     (b)  this subregulation has not already applied to submission services provided in response to an earlier application under Part 2 by the person proposing the same therapy involving the use of any of those drugs or medicinal preparations.

             (4)  This subregulation applies to a drug or medicinal preparation (the drug) on a day if:

                     (a)  on that day, the drug is a designated orphan drug; or

                     (b)  both:

                              (i)  on that day, the Secretary is yet to decide whether to include the drug in the Australian Register of Therapeutic Goods in response to an application made by the person on or before that day; and

                             (ii)  were the drug to be so included, both of the registration fees for doing so have been or would be waived under paragraph 45(12)(c) of the Therapeutic Goods Regulations 1990 because of the drug being a designated orphan drug; or

                     (c)  less than 12 months before that day, the drug was included in the Australian Register of Therapeutic Goods and both of the registration fees for doing so were waived under paragraph 45(12)(c) of the Therapeutic Goods Regulations 1990 because the drug was a designated orphan drug.

             (5)  For the purposes of paragraphs (4)(b) and (c), the registration fees are the fees described in paragraph 23B(2)(b) and subsection 24(1A) of the Therapeutic Goods Act 1989.

Application for the services should include reasons why any exemption applies

             (6)  An applicant for services who considers that subregulation (1) or (3) applies to the fee for the services, must include with the application for the services reasons why that subregulation would apply.

5.2  Waiver of fees

Waiver of fees under Division 1A.1 or Part 2 or 3

             (1)  The Secretary may, in writing and on request, decide whether or not to waive all or part of one or more fees:

                     (a)  payable by a person under Division 1A.1 or Part 2 or 3; and

                     (b)  for services that directly or indirectly relate to a Part 2 submission.

The request must be included in the person’s application under Part 2 or 3 for any of the services referred to in paragraph (b).

Note:          A request to waive fees payable under Division 1A.1 for ATAGI advice would need to be included in a related application for services under Part 2 or 3.

             (2)  The Secretary must decide under subregulation (1) to waive all or part of one or more those fees if:

                     (a)  the submission involves the public interest; and

                     (b)  payment of all of those fees would make the submission financially unviable.

             (3)  Without limiting subregulation (2), the submission involves the public interest if:

                     (a)  it concerns a drug, medicinal preparation or vaccine that would represent suitable therapy for a patient population; and

                     (b)  the patient population is not large enough to make the submission financially viable; and

                     (c)  the drug, medicinal preparation or vaccine is to be used:

                              (i)  for palliative care; or

                             (ii)  as a paediatric medicine; or

                            (iii)  for medical treatment of Aboriginal or Torres Strait Islander peoples.

             (4)  If:

                     (a)  as described in subregulation (1), a person requests the Secretary to waive all or part of a fee for services that directly or indirectly relate to a Part 2 submission; and

                     (b)  the Secretary decides under subregulation (1) not to do so;

the person may not later request the Secretary to waive all or part of that fee.

Waiver of fees for list management services

             (5)  The Secretary may, in writing and on request, decide whether or not to waive all or part of the fee payable by a person under Part 3A for list management services provided in response to a list management application.

             (6)  The request must be included in the list management application.

             (7)  The Secretary must decide under subregulation (5) to waive all or part of the fee if:

                     (a)  the list management application involves the public interest; and

                     (b)  payment of the fee would make that application financially unviable.

             (8)  Subregulation (3) applies to:

                     (a)  subregulation (7); and

                     (b)  a list management application referred to in subregulation (7);

in a corresponding way to the way that subregulation (3) applies to subregulation (2) and a submission referred to in subregulation (2).

Part 6Review of decisions

  

6.1A  Reviewable decisions

                   This Part applies to the following decisions (reviewable decisions) of the Secretary:

                     (a)  a decision under subregulation 1A.2(1) not to partially exempt a person (about ATAGI applications);

                     (b)  a decision under subregulation 2.15(3) that providing submission services in response to an application is not required to address an urgent public health need;

                     (c)  a decision under subregulation 2.20(1) determining the evaluation category of an application under Part 2;

                     (d)  a decision under subregulation 3.10(3) that providing pricing services in response to a pricing application is not required to address an urgent public health need;

                     (e)  a decision under subregulation 3.14(1) determining the category of a pricing application;

                      (f)  a decision under subregulation 5.2(1) or (5) (about waiving fees);

                     (g)  a decision under subregulation 6.3(2) (about decisions made on reviews initiated by the Secretary).

Note:          The decision could be made by a delegate of the Secretary (see subsection 6(5) of the Act).

6.1  Notice of review rights

             (1)  When the Secretary makes a reviewable decision referred to in paragraph 6.1A(b), (d) or (g) about a person, the Secretary must, within 14 days after making the decision, give the person:

                     (a)  written notice of the decision; and

                     (b)  a statement setting out particulars of the person’s review rights.

Note:          Notice of these things for the other kinds of reviewable decisions is given under other provisions of these Regulations.

             (2)  The notice must include particulars about how the person may respond to the notice.

             (3)  Failure to comply with subregulation (1) does not affect the validity of the decision.

6.2  Internal review

Initial internal review

             (1)  If a reviewable decision is made about a person, the person may apply in writing to the Secretary for review of the reviewable decision.

             (2)  The application must:

                     (a)  be made within:

                              (i)  14 days after the applicant received notice under these Regulations of the reviewable decision; or

                             (ii)  any longer period allowed by the Secretary; and

                     (b)  set out the reasons for making the application.

             (3)  The following person (the initial reviewer):

                     (a)  if the original decision maker of the reviewable decision is available—that person;

                     (b)  otherwise—a person authorised under subregulation (6);

must, within 14 days after receiving the application:

                     (c)  review the reviewable decision and decide (the initial review decision):

                              (i)  to affirm or vary the reviewable decision; or

                             (ii)  to revoke the reviewable decision, and make any other decision that the initial reviewer thinks appropriate; and

                     (d)  give written notice to the applicant of the initial review decision.

Further internal review

             (4)  The applicant may, within 14 days after receiving notice under paragraph (3)(d), request in writing to the Secretary, in accordance with the notice, that the Secretary review the initial review decision.

             (5)  The Secretary, or a person authorised under subregulation (6), (the further reviewer) must, within 14 days after receiving the request:

                     (a)  review the initial review decision and decide (the further review decision):

                              (i)  to affirm or vary the initial review decision; or

                             (ii)  to revoke the initial review decision, and make any other decision that the further reviewer thinks appropriate; and

                     (b)  give written notice to the applicant of the further review decision.

Persons authorised by the Secretary

             (6)  For the purposes of subregulation (3) or (5), the Secretary may in writing authorise an SES employee, or acting SES employee, in the Department to act under that subregulation.

             (7)  However, disregard a person’s authorisation for the purposes of subregulation (5) if the person was involved in making:

                     (a)  the initial review decision; or

                     (b)  the reviewable decision from which the initial review decision was made.

Discretion to suspend any services to which the review relates

             (8)  While an application or request for review is being considered under this regulation, the Commonwealth may suspend any services under these Regulations to which the reviewable decision relates.

6.3  Internal review—Secretary

             (1)  The Secretary may, at any time, initiate a review of a reviewable decision (other than an earlier decision under subregulation (2)).

Note:          The review could be initiated by a delegate of the Secretary (see subsection 6(5) of the Act).

             (2)  The Secretary may:

                     (a)  affirm, vary or revoke the decision; and

                     (b)  if the Secretary revokes the decision—make any other decision the Secretary thinks appropriate.

Note:          Notice must be given of a decision under this subregulation (see subregulation 6.1(1)).

6.4  Notice of fee adjustment

                   If a person has underpaid or overpaid a fee as a result of a decision made under the following provisions, the Secretary must, within 28 days after making the decision, notify the person accordingly:

                     (a)  paragraph 6.2(3)(c) (an initial review decision);

                     (b)  paragraph 6.2(5)(a) (a further review decision);

                     (c)  subregulation 6.3(2) (a Secretary‑initiated review decision).

Note:          A further payment, or a refund, will then be required (see subregulations 4.1(3) and (4)).

6.5  Review by the Administrative Appeals Tribunal

             (1)  Applications may be made to the Administrative Appeals Tribunal for review of a decision under paragraph 6.2(5)(a) of the further reviewer referred to in that paragraph.

             (2)  While such an application is being considered by the Administrative Appeals Tribunal, the Commonwealth may suspend any services under these Regulations to which the decision relates.

Part 7Application and transitional provisions

  

7.1  Application of these Regulations

                   These Regulations apply to applications received by the Department after 31 December 2009.

7.2  Application and transitional provisions for the National Health (Pharmaceuticals and Vaccines—Cost Recovery) Amendment Regulations 2019

             (1)  The amendments made by the amending instrument apply in relation to an application made under these Regulations on or after 1 July 2019, even if a related application under these Regulations was made before that day.

Example:    An application under Part 3 is made on 10 July 2019 that relates to an application under Part 2 that was made in January 2019. The amendments made by the amending instrument will apply in relation to the application under Part 3.

             (2)  However, these Regulations apply with the modifications described in subregulation (3) in relation to an application made under Part 2 on or after 1 July 2019 that:

                     (a)  is in the major evaluation category (see Subdivision 2 of Division 2.1); and

                     (b)  is for consideration at the Committee meeting in November 2019.

Note:          This means the amendments made by the amending instrument apply in relation to these particular Part 2 applications with the modifications in subregulation (3).

             (3)  These Regulations apply in relation to the application (the transitional application) as if:

                     (a)  the fee in item 1 of the table in subregulation 2.2(1) did not include an amount equal to the deposit referred to in subregulation 2.2(2); and

                     (b)  prior notice of the transitional application were not required under subregulation 2.15(1).

             (4)  Despite the amendments made by the amending instrument:

                     (a)  the old Regulations (other than Part 3) continue to apply on and after 1 July 2019 in relation to an application:

                              (i)  made under Part 2 of the old Regulations; and

                             (ii)  for which a notice under regulation 2.17 of the old Regulations has been given before 1 July 2019;

                            as if those amendments had not been made; and

                     (b)  Part 3 of the old Regulations continues to apply on and after 1 July 2019 in relation to an application:

                              (i)  made by a person under Part 2 of the old Regulations; and

                             (ii)  for which the Commonwealth has notified the person in writing before 1 July 2019 that the Commonwealth will begin pricing negotiations in response to a pricing offer sent by the person;

                            as if those amendments had not been made; and

                     (c)  the old Regulations continue to apply on and after 1 July 2019, in relation to an application submitted under regulation 4.3 of the old Regulations before 1 July 2019, as if those amendments had not been made.

Example:    A notice is sent under regulation 2.17 of the old Regulations in early 2019 about a person’s application under Part 2, and the Commonwealth notifies the person on 1 June 2019 that related pricing negotiations will begin. The old Regulations will continue to apply to anything done on and after 1 July 2019 in relation to the application or the pricing negotiations. For example:

(a)    an application to waive the evaluation fee or pricing fee would be made under subregulation 5.2(1) of the old Regulations; and

(b)    a notice about the Minister exercising a power relating to the pricing offer would be made under regulation 3.8 of the old Regulations.

             (5)  An application under Part 2 of the old Regulations ceases to have effect on 1 July 2019 unless it is covered by subregulation (4).

             (6)  In this regulation:

amending instrument means the National Health (Pharmaceuticals and Vaccines—Cost Recovery) Amendment Regulations 2019.

old Regulations means these Regulations (apart from this Part) as in force immediately before 1 July 2019.


Schedule 1Applications

(Division 2.1)

Part 1Vaccines

            1.1  To specify a vaccine to be a designated vaccine in a determination under subsection 9B (2) of the Act

            1.2  To vary the determination of a designated vaccine under subsection 9B (2) of the Act to change the way in which a vaccine has been specified

            1.3  To vary the determination of a designated vaccine under subsection 9B (2) to add a new circumstance in which the vaccine may be provided

            1.4  To vary the determination of a designated vaccine under subsection 9B (2) to change a circumstance in which the vaccine may be provided but not so as to add a new circumstance

Part 2Pharmaceuticals

            2.1  To declare a drug or medicinal preparation under subsection 85 (2) of the Act and, if applicable, subsection 85 (2A) of the Act

            2.2  To vary a declaration made under subsection 85 (2) of the Act and, if applicable, subsection 85 (2A) of the Act

            2.3  To specify circumstances, or vary an existing specification to add a new circumstance, in which a prescription for the supply of a pharmaceutical benefit may be written under subsection 85 (7) or paragraph 85 (8) (b) of the Act

            2.4  To vary an existing specification to change the circumstances in which a prescription for the supply of a pharmaceutical benefit may be written under subsection 85 (7) or paragraph 85 (8) (b) of the Act but not so as to add a new circumstance

            2.5  To determine, or vary a determination about:

                     (a)  a form of a listed drug under subsection 85 (3) of the Act; or

                     (b)  the manner of administration of a form of a listed drug under subsection 85 (5) of the Act

         2.5A  To determine, or vary a determination, that a pharmaceutical benefit (other than a pharmaceutical benefit that has a drug covered by subsection 85 (2A) of the Act) can only be supplied under special arrangements under section 100 of the Act

            2.6  To determine matters, or vary an existing determination of matters, for the writing of prescriptions by a specified class of persons under subsection 85A (2) of the Act

            2.7  To vary the specification of a pharmaceutical item under subsection 84AAA (2) of the Act so that it no longer applies to a pharmaceutical benefit

            2.8  To make a determination about the supply of a pharmaceutical benefit under section 93 or 93AA of the Act

            2.9  To make or vary a special arrangement under section 100 of the Act to provide for the supply of pharmaceutical benefits

          2.10  To specify a circumstance in which a pharmaceutical benefit may be supplied in a special arrangement made under section 100 of the Act, or to vary an existing special arrangement to specify a new circumstance

          2.11  To vary the circumstances in which a pharmaceutical benefit may be supplied in an existing special arrangement made under section 100 of the Act but not so as to add a new circumstance

          2.15  To agree on a new price for a single brand of a combination item under subsection 99ACC(3) of the Act

Note:          The Committee may advise the Minister about this under subsection 101(4AC) of the Act.

          2.16  To determine that a pharmaceutical item is an exempt item under section 84AH of the Act

Note:          The Committee may advise the Minister about this under subsection 101(4AB) of the Act.

          2.17  To revoke or vary a declaration under subsection 85 (2A) of the Act so that a listed drug is generally available for supply under Part VII of the Act rather than available only under special arrangements under section 100 of the Act

Part 3Existing pharmaceutical items

            3.1  To determine a brand under subsection 85 (6) of the Act for a pharmaceutical item that has a listed brand

Schedule 2Medicinal preparations

(regulations 2.9 and 2.13)

  

              1.  The medicinal preparation is a pharmaceutical item that includes a substance, or has the form, mentioned in the following table:

 

Item

Substance or form

1

somatropin

2

a glucose indicator

 


Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.

 

Endnote 2—Abbreviation key

 

ad = added or inserted

o = order(s)

am = amended

Ord = Ordinance

amdt = amendment

orig = original

c = clause(s)

par = paragraph(s)/subparagraph(s)

C[x] = Compilation No. x

    /sub‑subparagraph(s)

Ch = Chapter(s)

pres = present

def = definition(s)

prev = previous

Dict = Dictionary

(prev…) = previously

disallowed = disallowed by Parliament

Pt = Part(s)

Div = Division(s)

r = regulation(s)/rule(s)

ed = editorial change

reloc = relocated

exp = expires/expired or ceases/ceased to have

renum = renumbered

    effect

rep = repealed

F = Federal Register of Legislation

rs = repealed and substituted

gaz = gazette

s = section(s)/subsection(s)

LA = Legislation Act 2003

Sch = Schedule(s)

LIA = Legislative Instruments Act 2003

Sdiv = Subdivision(s)

(md) = misdescribed amendment can be given

SLI = Select Legislative Instrument

    effect

SR = Statutory Rules

(md not incorp) = misdescribed amendment

Sub‑Ch = Sub‑Chapter(s)

    cannot be given effect

SubPt = Subpart(s)

mod = modified/modification

underlining = whole or part not

No. = Number(s)

    commenced or to be commenced

 

Endnote 3—Legislation history

 

Number and year

Registration

Commencement

Application, saving and transitional provisions

No 372, 2009

16 Dec 2009 (F2009L04013)

1 Jan 2010 (r 1.2)

 

No 294, 2010

25 Nov 2010 (F2010L02952)

1 Dec 2010 (r 2)

r 4

No 120, 2011

30 June 2011 (F2011L01364)

Sch 2 (item 51): 1 July 2011 (r 2)

 

Name

Registration

Commencement

Application, saving and transitional provisions

Biosecurity (Consequential Amendments and Transitional Provisions) Regulation 2016

9 May 2016 (F2016L00717)

Sch 2 (item 25) and Sch 3: 16 June 2016 (s 2(1) item 1)

Sch 3

National Health (Pharmaceuticals and Vaccines—Cost Recovery) Amendment Regulations 2019

9 Apr 2019 (F2019L00579)

1 July 2019 (s 2(1) item 1)

National Health (Pharmaceuticals and Vaccines—Cost Recovery) Amendment (Vaccine Advice) Regulations 2019

28 June 2019 (F2019L00931)

1 July 2019 (s 2(1) item 1)

 

Endnote 4—Amendment history

 

Provision affected

How affected

Part 1

 

r 1.2..........................................

rep LA s 48D

r 1.3..........................................

am F2019L00579; F2019L00931

Part 1A

 

Part 1A......................................

ad F2019L00579

Division 1A.1

 

r 1A.1.......................................

ad F2019L00579

 

rs F2019L00931

r 1A.2.......................................

ad F2019L00579

 

am F2019L00931

r 1A.3.......................................

ad F2019L00579

r 1A.4.......................................

ad F2019L00579

r 1A.5.......................................

ad F2019L00579

r 1A.6.......................................

ad F2019L00579

Division 1A.2

 

r 1A.7.......................................

ad F2019L00579

r 1A.8.......................................

ad F2019L00579

r 1A.9.......................................

ad F2019L00579

r 1A.10.....................................

ad F2019L00579

r 1A.11.....................................

ad F2019L00579

r 1A.12.....................................

ad F2019L00579

Part 2

 

Part 2 heading...........................

rs F2019L00579

Division 2.1A

 

Division 2.1A...........................

ad F2019L00579

r 2.1A.......................................

ad F2019L00579

Division 2.1

 

Division 2.1 heading.................

rs F2019L00579

Subdivision 1

 

Subdivision 1............................

rs F2019L00579

r 2.1..........................................

rs F2019L00579

r 2.2..........................................

rs F2019L00579

Subdivision 2

 

r 2.3..........................................

am F2019L00579

r 2.4..........................................

am No 294, 2010; F2019L00579

Subdivision 3

 

r 2.7..........................................

am No 294, 2010; F2019L00579

r 2.8..........................................

am No 294, 2010; F2019L00579

r 2.9..........................................

am No 294, 2010; F2019L00579

r 2.10........................................

am F2019L00579

Subdivision 4

 

r 2.12........................................

am No 294, 2010; F2019L00579

r 2.13........................................

am No 294, 2010; F2019L00579

r 2.14........................................

am No 294, 2010; F2019L00579

Subdivision 5............................

rep F2019L00579

Division 2.2

 

Division 2.2..............................

rs F2019L00579

r 2.15........................................

rs F2019L00579

r 2.16........................................

am No 294, 2010

 

rs F2019L00579

r 2.17........................................

rs F2019L00579

r 2.18........................................

rs F2019L00579

r 2.19........................................

rs F2019L00579

Division 2.3

 

Division 2.3..............................

ad F2019L00579

r 2.20........................................

rs F2019L00579

r 2.21........................................

ad F2019L00579

Part 3

 

Part 3........................................

rs F2019L00579

Division 3.1

 

r 3.1..........................................

am No 294, 2010

 

rs F2019L00579

Division 3.2

 

r 3.2..........................................

rs F2019L00579

r 3.3..........................................

am No 294, 2010

 

rs F2019L00579

r 3.4..........................................

am No 294, 2010

 

rs F2019L00579

r 3.5..........................................

rs F2019L00579

r 3.6..........................................

am No 294, 2010

 

rs F2019L00579

r 3.7..........................................

rs F2019L00579

r 3.8..........................................

am No 294, 2010

 

rs F2019L00579

r 3.9..........................................

ad F2019L00579

Division 3.3

 

r 3.10........................................

ad F2019L00579

r 3.11........................................

ad F2019L00579

r 3.12........................................

ad F2019L00579

r 3.13........................................

ad F2019L00579

Division 3.4

 

r 3.14........................................

ad F2019L00579

Part 3A

 

Part 3A......................................

ad F2019L00579

r 3A.1.......................................

ad F2019L00579

r 3A.2.......................................

ad F2019L00579

r 3A.3.......................................

ad F2019L00579

r 3A.4.......................................

ad F2019L00579

Part 4

 

Part 4 heading...........................

rs F2019L00579

r 4.1..........................................

rs F2019L00579

r 4.2..........................................

rs F2019L00579

r 4.3..........................................

am No 294, 2010; F2019L00579

r 4.4..........................................

rep F2019L00579

r 4.5..........................................

rep F2019L00579

r 4.6..........................................

rep F2019L00579

r 4.7..........................................

am F2019L00579

Part 5

 

r 5.1..........................................

am No 294, 2010; No 120, 2011; F2016L00717; F2019L00579

r 5.2..........................................

am F2019L00579

Part 6

 

r 6.1A.......................................

ad F2019L00579

r 6.1..........................................

am F2019L00579

r 6.2..........................................

rs F2019L00579

r 6.3..........................................

rs F2019L00579

r 6.4..........................................

rs F2019L00579

r 6.5..........................................

rs F2019L00579

Part 7

 

Part 7 heading...........................

rs F2019L00579

r 7.2..........................................

ad F2019L00579

Schedule 1

 

Schedule 1................................

am No 294, 2010; F2019L00579

Schedule 2

 

Schedule 2................................

am No 294, 2010

Schedule 3................................

rep F2019L00579

Schedule 4................................

rep F2019L00579